Search

We review the highest-value deals of the year with the help of DealForma.

The COVID-19 pandemic dealt a blow to the deals landscape in early 2020, but the sector bounced back.

The development of antibodies and associated technologies continues to drive high-value deals. We look at recent trends in the field with help from DealForma.

In the past decade, deals involving rare diseases have increased in size and value, supported by the growing number of opportunities based on novel therapeutic platforms.

Partnerships are playing an important role in the pursuit of coronavirus-specific antibodies for diagnostics and therapies for COVID‑19.

M&A activity in the biopharma industry continued to boom last year, with more than 200 deals collectively worth over $200 billion.

The emergence of COVID-19 sparked a huge increase in the volume of infectious disease deals in 2020, but how has the market fared in the past year?

After an unusual year, M&A activity picked up again in the biopharma industry with a number of billion-dollar deals.

Dealmaking is returning to pre-pandemic levels with numerous billion-dollar deals being signed, many focusing on immuno-oncology and inflammation.

Recent major antibody deals involve immune checkpoint inhibitors, antibody–drug conjugates and natural killer cell engagers for cancer.

Since 2021, the oncology sector has seen a string of billion-dollar deals.

Approaches such as gene therapy and nucleic acid-based therapies are emerging in recent deals related to potential treatments for ophthalmic diseases.

Big pharma dealmaking returns to pre-pandemic levels as companies spend big to develop a range of cancer therapies.

Over the past year, the biopharma industry has witnessed some landmark approvals, high-value merger and acquisition deals and phenomenal venture funding in the US. In this feature, we chart the key trends in biopharma dealmaking since June 2018.

Companies that have pioneered platforms based on oligonucleotides targeting RNA and their biopharma partners continue to move beyond rare diseases into broader patient populations with cardiovascular diseases and central nervous system disorders.